427 related articles for article (PubMed ID: 25381393)
1. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
Lee AM; Shi Q; Pavey E; Alberts SR; Sargent DJ; Sinicrope FA; Berenberg JL; Goldberg RM; Diasio RB
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25381393
[TBL] [Abstract][Full Text] [Related]
2. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).
Lee AM; Shi Q; Alberts SR; Sargent DJ; Sinicrope FA; Berenberg JL; Grothey A; Polite B; Chan E; Gill S; Kahlenberg MS; Nair SG; Shields AF; Goldberg RM; Diasio RB
Pharmacogenet Genomics; 2016 Mar; 26(3):133-7. PubMed ID: 26658227
[TBL] [Abstract][Full Text] [Related]
3. Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
Wagner AD; Grothey A; Andre T; Dixon JG; Wolmark N; Haller DG; Allegra CJ; de Gramont A; VanCutsem E; Alberts SR; George TJ; O'Connell MJ; Twelves C; Taieb J; Saltz LB; Blanke CD; Francini E; Kerr R; Yothers G; Seitz JF; Marsoni S; Goldberg RM; Shi Q
J Natl Cancer Inst; 2021 Apr; 113(4):400-407. PubMed ID: 32835356
[TBL] [Abstract][Full Text] [Related]
4. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
[TBL] [Abstract][Full Text] [Related]
5. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
Falvella FS; Cheli S; Martinetti A; Mazzali C; Iacovelli R; Maggi C; Gariboldi M; Pierotti MA; Di Bartolomeo M; Sottotetti E; Mennitto R; Bossi I; de Braud F; Clementi E; Pietrantonio F
Br J Clin Pharmacol; 2015 Sep; 80(3):581-8. PubMed ID: 25782327
[TBL] [Abstract][Full Text] [Related]
6. DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial.
Boige V; Vincent M; Alexandre P; Tejpar S; Landolfi S; Le Malicot K; Greil R; Cuyle PJ; Yilmaz M; Faroux R; Matzdorff A; Salazar R; Lepage C; Taieb J; Laurent-Puig P
JAMA Oncol; 2016 May; 2(5):655-662. PubMed ID: 26794347
[TBL] [Abstract][Full Text] [Related]
7. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
[TBL] [Abstract][Full Text] [Related]
8. The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
Maharjan AS; McMillin GA; Patel GK; Awan S; Taylor WR; Pai S; Frankel AE; Nelson C; Wang B; Hosein PJ; Singh AP; Khushman M
Clin Colorectal Cancer; 2019 Sep; 18(3):e280-e286. PubMed ID: 31160238
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients.
Negarandeh R; Salehifar E; Saghafi F; Jalali H; Janbabaei G; Abdhaghighi MJ; Nosrati A
BMC Cancer; 2020 Jun; 20(1):560. PubMed ID: 32546132
[TBL] [Abstract][Full Text] [Related]
10. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.
Gross E; Busse B; Riemenschneider M; Neubauer S; Seck K; Klein HG; Kiechle M; Lordick F; Meindl A
PLoS One; 2008; 3(12):e4003. PubMed ID: 19104657
[TBL] [Abstract][Full Text] [Related]
11. DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.
Nahid NA; Apu MNH; Islam MR; Shabnaz S; Chowdhury SM; Ahmed MU; Nahar Z; Islam MS; Islam MS; Hasnat A
Cancer Chemother Pharmacol; 2018 Jan; 81(1):119-129. PubMed ID: 29134491
[TBL] [Abstract][Full Text] [Related]
12. DPYD variants to predict 5-FU toxicity: the ultimate proof.
Innocenti F
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25381394
[No Abstract] [Full Text] [Related]
13. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
Ruzzo A; Graziano F; Galli F; Galli F; Rulli E; Lonardi S; Ronzoni M; Massidda B; Zagonel V; Pella N; Mucciarini C; Labianca R; Ionta MT; Bagaloni I; Veltri E; Sozzi P; Barni S; Ricci V; Foltran L; Nicolini M; Biondi E; Bramati A; Turci D; Lazzarelli S; Verusio C; Bergamo F; Sobrero A; Frontini L; Menghi M; Magnani M
Br J Cancer; 2017 Oct; 117(9):1269-1277. PubMed ID: 29065426
[TBL] [Abstract][Full Text] [Related]
14. New advances in DPYD genotype and risk of severe toxicity under capecitabine.
Etienne-Grimaldi MC; Boyer JC; Beroud C; Mbatchi L; van Kuilenburg A; Bobin-Dubigeon C; Thomas F; Chatelut E; Merlin JL; Pinguet F; Ferrand C; Meijer J; Evrard A; Llorca L; Romieu G; Follana P; Bachelot T; Chaigneau L; Pivot X; Dieras V; Largillier R; Mousseau M; Goncalves A; Roché H; Bonneterre J; Servent V; Dohollou N; Château Y; Chamorey E; Desvignes JP; Salgado D; Ferrero JM; Milano G
PLoS One; 2017; 12(5):e0175998. PubMed ID: 28481884
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
Henricks LM; van Merendonk LN; Meulendijks D; Deenen MJ; Beijnen JH; de Boer A; Cats A; Schellens JHM
Int J Cancer; 2019 May; 144(9):2347-2354. PubMed ID: 30485432
[TBL] [Abstract][Full Text] [Related]
16. 5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX.
Onesti CE; Botticelli A; La Torre M; Borro M; Gentile G; Romiti A; Lionetto L; Petremolo A; Occhipinti M; Roberto M; Falcone R; Simmaco M; Marchetti P; Mazzuca F
Anticancer Drugs; 2017 Mar; 28(3):322-326. PubMed ID: 27845948
[TBL] [Abstract][Full Text] [Related]
17. Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common DPYD Polymorphisms.
Falvella FS; Luoni M; Cheli S; Fava S; Cergnul M
Chemotherapy; 2017; 62(5):323-326. PubMed ID: 28614820
[TBL] [Abstract][Full Text] [Related]
18. A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant.
De Falco V; Natalicchio MI; Napolitano S; Coppola N; Conzo G; Martinelli E; Zanaletti N; Vitale P; Giunta EF; Vietri MT; Vitiello PP; Ciardiello D; Marinaccio A; De Vita F; Ciardiello F; Troiani T
Medicine (Baltimore); 2019 May; 98(21):e15759. PubMed ID: 31124962
[TBL] [Abstract][Full Text] [Related]
19. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.
Saif MW
Cancer Genomics Proteomics; 2013; 10(2):89-92. PubMed ID: 23603345
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
Meulendijks D; Henricks LM; Sonke GS; Deenen MJ; Froehlich TK; Amstutz U; Largiadèr CR; Jennings BA; Marinaki AM; Sanderson JD; Kleibl Z; Kleiblova P; Schwab M; Zanger UM; Palles C; Tomlinson I; Gross E; van Kuilenburg AB; Punt CJ; Koopman M; Beijnen JH; Cats A; Schellens JH
Lancet Oncol; 2015 Dec; 16(16):1639-50. PubMed ID: 26603945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
